Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00097942 · ClinicalTrials.gov registry record · Phase 2
Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients
A Phase 2 study, sponsored by Forest Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 138
- Enrollment target
NCT00097942 is a Phase 2 study that has completed, run by Forest Laboratories. The registered enrollment target is 138 participants.
The verdict
NCT00097942, a Phase 2 study, has completed, sponsored by Forest Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 138 participants
- Enrollment target
Study Summary
Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy with memantine will reduce NMDA receptor hyperactivity, improving signal to noise ratio and thereby improving cognitive symptoms.
Interventions
- DRUG memantine HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2004-08 |
| Est. Completion | 2005-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00097942
The ClinicalTrials.gov registry entry for NCT00097942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 138 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Forest Laboratories, which has 145 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which memantine HCl is the first listed.
NCT00097942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00097942 about?
NCT00097942 is a clinical study titled "Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients". Standard antipsychotic drug regimens do not fully address the impact of cognitive symptoms associated with schizophrenia. The NMDA receptor has been connected to the pathophysiology of schizophrenia. Memantine is an uncompetitive NMDA receptor antagonist. It is hypothesized that adjunctive therapy w...
What is the current status of trial NCT00097942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 138 participants. The study started on 2004-08. Estimated completion is 2005-09.
What interventions are being tested in trial NCT00097942?
The interventions under investigation include: memantine HCl (DRUG).
Who is sponsoring clinical trial NCT00097942?
This trial is sponsored by Forest Laboratories, which has 145 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.